Evidence map›Paper›PMID 37205550›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: an individual isolate metaanalysis.

Camus Nimmo, Neda Bionghi, Matthew J Cummings, Rubeshan Perumal, Madeleine Hopson, Shamim Al Jubaer, Allison Wolf, Barun Mathema, Michelle H Larsen, Max O'Donnell

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Camus NimmoFrancis Crick Institute, London, UK.
Neda BionghiDepartment of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, USA.
Matthew J CummingsDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Rubeshan PerumalCAPRISA-MRC HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
Madeleine HopsonDepartment of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, USA.
Shamim Al JubaerDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY.
Allison WolfDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Barun MathemaDepartment of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA.
Michelle H LarsenDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY.
Max O'DonnellDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Columbia University Irving Medical Center · USAlbert Einstein College of Medicine · USNewYork–Presbyterian Hospital · USSouth African Medical Research Council · ZAThe Francis Crick Institute · GB

Funding

Novel Reporter Phages to Detect Complex TB Drug Resistance and PersistenceR01AI114900 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Michelle H Larsen, Max O'Donnell · 2015 to 2026
$7.2M
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South AfricaR01AI167795 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Max O'Donnell · 2022 to 2026
$2.9M
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South AfricaR01AI124413 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX, PADAYATCHI, NESRI · 2016 to 2020
$2.7M
Subtyping sepsis in Uganda using clinical, pathogen, and host response profilingK23AI163364 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CUMMINGS, MATTHEW JOHN · 2022 to 2025
$733k
NIAID NIH HHS K23 AI163364NIAID NIH HHS R01 AI114900NIAID NIH HHS R01 AI124413NIAID NIH HHS R01 AI167795Wellcome Trust CC2169
6 · The paper itself

Abstract

Background: Clinical bedaquiline resistance predominantly involves mutations in Methods: We screened public databases for articles published until October 2022. Eligible studies performed sequencing of at least Results: Eighteen eligible studies were identified, comprising 975 Discussion: Sequencing candidate genes is insufficiently sensitive to diagnose clinical bedaquiline resistance, but where identified a limited number of mutations should be assumed to be associated with resistance. Genomic tools are most likely to be effective in combination with rapid phenotypic diagnostics.

Identifiers

PMID37205550
PMCPMC10187448
OpenAlexW4372347375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.